Deutsche Bank lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 750 from DKK 815 and keeps a Hold rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application
- Zealand Pharma says FDA issues CRL for glepaglutide NDA
- Zealand Pharma announces first participant enrolled in ZUPREME-1
- Zealand Pharma upgraded to Hold from Sell at Danske Bank
- Zealand Pharma initiated with an Overweight at JPMorgan
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue